Juveacell 8% (hECM Booster, Similar with Re2O & Cellredm)

Main Ingredients:

• Acellular Dermal Matrix – micronized hADM (Injectable Human ADM) 8%

Packing Unit:

• 1 × 1.0 cc pre-filled syringe/box

Description

juveàcell 8% is an injectable human Acellular Dermal Matrix (hADM) product developed by VAIM Co., Ltd. for skin reconstruction. The name juveàcell is derived from the combination of "Juve" (youth) and "Cell", embodying the philosophy of restoring the natural vitality of cells and gifting the skin with new time — a protector of natural cellular vitality. Formulated with 8% micronized human-derived ADM, it preserves collagen, elastin and over 30 extracellular matrix (ECM) growth factors within the dermal scaffold. Unlike volumising fillers, juveàcell is designed to support the skin's structural foundation by supplying biocompatible ECM components that assist natural cellular recovery and dermal regeneration. The product is manufactured using the proprietary Ecell™ Technology — a supercritical CO₂ fluid-based decellularisation process — which removes cellular components while preserving the ECM architecture, avoiding surfactant use to minimise residual toxicity. Supplied sterile in a ready-to-use pre-filled syringe, stored at room temperature (1–30°C).

Benefits:

• Supplies biocompatible hADM scaffold rich in collagen, elastin and 30+ ECM growth factors to support dermal repair
• Proprietary Ecell™ supercritical CO₂ decellularisation preserves the ECM structure while eliminating cellular components
• CO₂-based processing replaces surfactants, minimising residual toxicity and reducing the risk of allergic reaction
• Designed for skin reconstruction rather than volumisation — supports the skin's intrinsic cellular recovery mechanism
• High biocompatibility as a human-derived tissue product (인체조직)
• Patent-pending Ecell™ Technology (제10-2025-0039562 / 제10-2022-0043858)
• Convenient ready-to-use pre-filled syringe format

Application Areas:

• Facial skin reconstruction and overall skin quality improvement
• Fine lines and early skin laxity requiring ECM-level structural support
• Skin thinning and loss of dermal density across multiple facial zones
• Post-procedural skin recovery support under physician discretion
• Complementary skin-booster treatment alongside other aesthetic procedures